Dr. Tobias Kruse, our CEO, participated in the Swiss Biotech Day in Basel, Switzerland. He observed that investor interest in biotech is showing signs of recovery after a period of reduced investments due to the COVID-19 pandemic and higher interest rates.
This renewed investor interest could lead to more funding for biotech ventures and the start of new clinical trials, benefiting vendors like us who support patient recruitment.
Dr. Kruse also valued reconnecting with industry peers and partners, anticipating continued progress leading up to the next Swiss Biotech Day in 2025.
Trials24 GmbH
Trials24 accelerates patient recruitment to support biopharmaceutical companies and CROs complete their clinical trials on time, bringing innovative drugs to patients faster.
© Copyright | Trials24 GmbH
